Global Lung Cancer Diagnostics Strategic Research Report 2023: Imaging Tests Segment and US Leads, Molecular Tests Category and Asia-Pacific to Witness Growth


Dublin, Oct. 27, 2023 (GLOBE NEWSWIRE) -- The "Lung Cancer Diagnostics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Global Lung Cancer Diagnostics Market to Reach $4.7 Billion by 2030

The global market for Lung Cancer Diagnostics estimated at US$2.6 Billion in the year 2022, is projected to reach a revised size of US$4.7 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2022-2030.

Additionally, the dataset segments the market into various diagnostic methods, such as Imaging Tests, Sputum Cytology, Molecular Tests, Biopsy, and Other Tests, providing sales analysis for each category. It also delves into specific types of lung cancer, including Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC), as well as the end-users of these diagnostic services, including Hospital Laboratories, Cancer Research Institutes, and Other End-Uses.

Imaging Tests, one of the segments analyzed in the report, is projected to record 7.4% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Sputum Cytology segment is estimated at 7.9% CAGR for the next 8-year period.

The dataset also includes historical data for the years 2014 through 2021, offering insights into the market's growth over time. It further provides a 16-year perspective for the years 2014, 2023, and 2030, with a percentage breakdown of value sales by geographic region, allowing for a comprehensive understanding of the global Lung Cancer Diagnostics market.

The U.S. Market is Estimated at $675 Million, While China is Forecast to Grow at 11.3% CAGR

The Lung Cancer Diagnostics market in the U.S. is estimated at US$675 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2022 to 2030.

This dataset provides a detailed analysis of the global Lung Cancer Diagnostics market. It includes recent, current, and future assessments of the market's performance across various geographic regions, such as the USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. The analysis is presented in terms of annual sales in US$ Thousand for the years 2022 through 2030, along with corresponding percentage Compound Annual Growth Rates (% CAGR).

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Early Detection of Lung Cancer Takes Precedence, Driving the Demand for Lung Cancer Diagnostics
  • Non-small Cell Lung Cancer - The More Prominent of the Two Lung Cancer Types
  • Imaging Tests Segment Dominates the Market, Molecular Tests Category to Witness High Growth
  • US Leads the Lung Cancer Diagnostics Market, Asia-Pacific to Witness Fastest Growth
  • Lung Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2023 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • Impact of Covid-19 and a Looming Global Recession

MARKET TRENDS & DRIVERS

  • Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Early Diagnoses
  • Age-Standardized Lung Cancer Rates for Select Countries
  • Age-Standardized Lung Cancer Rates in Men for Select Countries
  • Age Standardized Lung Cancer Rates in Women for Select Countries
  • Lung Cancer-Specific Biomarkers to Spur Market Growth
  • Select Lung Cancer Biomarkers
  • New Potential Biomarker for Early Stage Lung Cancer Identified in a Recent NCI Study (2019)
  • Advancements and Research Initiatives in Lung Cancer Diagnostics Space
  • EFIRM Test for Detection of Lung Cancer-related EGFR Mutations in NSCLC Patients
  • A Glance at Select Recent Launches of Lung Cancer Diagnostic Tests
  • New Product Launches/Approvals in the Lung Cancer Diagnostics
  • Recent Approvals
  • Liquid Biopsies Grow in Value as a Diagnostic Tool Supporting Therapy Decisions in NSCLCs
  • Effervescent Rate of New Innovations & Product Development Will Make Liquid Biopsy a Readily Available Option for Patients in the Coming Years
  • High Cigarette Consumption/Rise in Prevalence of Smoking Increases the Incidence of Lung Cancer
  • Cigarette Consumption Per Year Per Person Across Select Countries: 2016
  • Top 15 Countries with the Highest Smoking Rates: 2015
  • Increasing Number of Awareness Programs for Lung Cancer and Symptoms
  • Growing Availability of Government/Private Funding for R&D to Develop Lung Cancer Diagnostics
  • National Cancer Institute Research Funding for Lung Cancer in US$ Million for the Years 2014 through 2017
  • Aging Demographics & Unhealthy Lifestyles Raise the Risk of Cancer
  • Cancer Prone Sites based on Age
  • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050

FOCUS ON SELECT PLAYERS(Total 48 Featured)

  • Myriad Genetics, Inc.
  • F. Hoffmann-La Roche AG
  • Biocartis NV
  • Epigenomics AG
  • Biodesix, Inc.
  • Exosome Diagnostics, Inc.
  • Admera Health
  • Dr Lal PathLabs Ltd.
  • Guardant Health, Inc.
  • Oncimmune Holding PLC
  • Blueprint Genetics OY
  • CellMax Life, Inc.
  • Circulogene
  • BGI Genomics Co Ltd.
  • Inivata Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/j1ziwa

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data